The primary therapeutic role of this preparation, as an antiseptic agent, is to provide localized anti-infective support and symptomatic relief in the oral and pharyngeal areas. It is commonly used across conditions presenting with acute or disruptive symptom patterns caused by microbial factors.

This medicine helps address symptom clusters associated with microbial imbalances in situations involving soreness and irritation of the throat. It is considered relevant in contexts involving inflammatory or irritative states such as pharyngitis, tonsillitis, gingivitis, and oral candidiasis. It helps address symptom clusters associated with microbial imbalances, including certain recurrent or episodic manifestations like aphthous ulcers.

In addition to acute relief, the preparation is also relevant in specific clinical scenarios, often used as an aid for postoperative hygiene following minor oral surgery, and for managing microbial-related bad breath and controlling dental plaque. The overall goal is to contribute to easing the overall symptom load and improving day-to-day comfort during these symptomatic periods.

---

Quick Fact: Relief for Acute Sore Throat The preparation is commonly used at the first sign of throat pain and irritation to provide supportive, localized symptomatic relief.

This section outlines the population eligibility and non-eligibility for Hexetidine-based products, as defined in official regulatory documents.

Eligibility Scope

Category	Official Regulatory Status (As stated in label)
Populations for whom use is allowed	Adults and Adolescents aged 12 years and over.
Populations for whom use is not recommended	Children under 12 years of age.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance Hexetidine or any excipients.

---

Age-Related and Physiological Rules

Category	Official Regulatory Status (As stated in label)
Age-related eligibility rules	Contraindicated/Not Recommended in those under 12 years due to insufficient data to establish safety and efficacy.
Condition-specific eligibility rules	Caution required for patients with liver disease or epilepsy due to the ethanol content that must be taken into account.
Pregnancy and lactation eligibility status	No formal studies have been conducted in pregnant women; use is unlikely to present a risk due to negligible systemic absorption, but must be considered.
Eligibility-related restrictions	The product must not be swallowed and is not suitable for persistent symptoms.

---

Resulting Eligibility Structure

Official eligibility statements:

• Use is contraindicated in patients with a known hypersensitivity to hexetidine or any of the product’s excipients.
• The medicine is not recommended or contraindicated for use in children under 12 years of age.
• The product must not be swallowed; it is for external oromucosal use only.
• Use requires special caution in patients with liver disease or epilepsy due to the presence of ethanol in the formulation.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on hypersensitivity, a clear minimum age threshold of 12 years, and specific conditional use warnings for populations sensitive to the product's ethanol content. Use is restricted to adults and adolescents over 12 who do not have documented contraindications.

Interactions with other medicines and products

Official regulatory documentation establishes that the interaction profile for this medicine is characterized by a high degree of specificity related to its topical action. As a preparation intended for local application to the oral mucosa, systemic absorption of the active ingredient, Hexetidine, is minimal.

Active Ingredient Interaction Status

Regulatory sources explicitly state that no interactions are known for the active substance, Hexetidine, with other medicinal products. This classification confirms that there are no documented pharmacokinetic or pharmacodynamic interactions, which means the regulatory label does not include any mandatory restrictions concerning co-administration or separation of doses based on the active ingredient.

Excipient-Based Interaction and Constraints

The formulation is prepared in a hydroalcoholic base and therefore contains Ethanol (alcohol). This excipient is the basis for the medicine's only documented interaction constraints.

1. Risk upon Swallowing: Official documentation cautions that if the medicine is swallowed, the alcohol content has the potential to alter the effects of other medicinal products that are being taken.

2. Population-Specific Note: Due to the ethanol component, the regulatory text requires a specific caution: individuals who are addicted to alcohol must consult a healthcare professional before using the preparation.

The active substance, Hexetidine, exerts its antimicrobial effect through the disruption of microbial metabolism. The hexetidine molecule functions as a competitive inhibitor of thiamine-dependent enzymes within the microbial cell, interfering with essential oxidative processes. This interaction prevents energy production and leads to the suppression of bacterial and fungal proliferation, ultimately resulting in the loss of cellular viability. The systemic physiological consequence is a localized reduction in the microbial load on the mucous membrane.

The secondary component, Menthol, acts locally by modulating sensory function. Menthol engages TRPM8 cold receptors in the mucosal lining. This interaction initiates a sensory depolarization followed by desensitization of local afferent nerve endings at the application site.

Official Administration Guidelines

The usage of Стопангин-Тева (Hexetidine 0.1% solution) follows specific established instructions. The administration is strictly limited to the local application site and is designed as a short-term, non-systemic regimen.

Instruction Entity	Official Label Guideline
Route of administration	Oromucosal use only.
Dosing schedule	At least 15 ml of solution per single dose application.
Frequency and timing	Use is scheduled two to three times a day.
Preparation requirements	The solution must be used undiluted for gargling or rinsing the oral cavity.
Age-group rules	The standard regimen is for Adults and adolescents 12 years and over. Use in children under 12 years is not recommended.
Special conditions	The solution must not be swallowed and must be spit out after application. Adult supervision is required for children during use.

---

Administration Classification and Protocol

Classification	Description based on Official Instructions
Administration method	Topical (local application via gargle or rinse).
Frequency pattern	Daily (scheduled use).
Use-context constraints	Use is limited to a short-term basis and is not suitable for persistent symptoms.

The official instructions define the use of the medicine as a standardized, topical procedure for local administration. This protocol dictates the required 15 ml dose and two-to-three-times daily frequency, while procedural steps emphasize that the solution must be expectorated to ensure the administration remains strictly local. The specified regimen and age limits are established to structure the consistent application of the product.

Research evidence / Overview of Studies for Стопангин-Тева

Evidence for Use in Managing Dental Plaque and Gingivitis

Research has examined outcomes such as patient-reported outcomes describing perceived discomfort and changes in the oral environment. The research structure is primarily characterized by systematic reviews and controlled clinical trials which monitored outcomes such as plaque accumulation scores and gingival inflammation indices in populations consisting of systemically healthy adults included in trials focused on mild dental plaque or gingivitis.

The findings describe patterns observed in the studies where plaque measurements was observed in some studies to be lower compared to controls. However, the evidence quality varies across studies, and research exploring longer-term use findings were mixed. The trials conducted often included comparisons to other known antiseptic agents, and data show patterns related to performance differences when compared directly against certain other established compounds.

Evidence for Acute Sore Throat and Oropharyngeal Symptoms

The preparation was evaluated in research exploring outcomes capturing phases of heightened symptom activity associated with acute conditions such as pharyngitis or tonsillitis. The evidence here is derived primarily from short-term Randomized Controlled Trials (RCTs). These trials were used in research exploring how symptoms change over time in outpatients, with researchers focused on objective physical signs like throat redness (rubor) and swelling (tumefaction), as well as subjective reports of difficulty swallowing (dysphagia).

Research highlights changes measured during the study period. In research exploring short-term symptom changes, findings were restricted to the very short-term nature of the trials, often lasting only a few days. Comparative trials exploring temporary physiological imbalance data show patterns related to other, often multi-ingredient, antiseptic sprays sometimes appearing to be associated with a more pronounced change in objective clinical measurements.

Evidence Gaps and Areas of Uncertainty

The body of research involves limited data and certainty remains low for definitive long-term effects. The research base is characterized by small sample sizes, and follow-up durations were limited, providing limited information for long-term outcomes. Furthermore, data for certain groups remain insufficient, as there are few dedicated clinical trials exploring the application in children or older adults. The research contributes to the broader evidence landscape and clarifies what is still uncertain.

Key Studies & References

1. Antiinfectives and antiseptics for local oral treatment, ATC code A01AB12 (Hexetidine) classification
2. Hexetidine Drug Information (General Pharmacological Action and Uses)

Common questions about Стопангин-Тева (FAQ)

---

Q: Can Стопангин-Тева be used for treating tonsillitis?

According to official product information, this medicine is indicated for use as a local antiseptic, primarily for infections of the oral and pharyngeal mucosa. While antiseptic properties are intended to manage the microbial load associated with these conditions, the specific therapeutic conditions approved for treatment, such as tonsillitis, should be confirmed on the official product label.

---

Q: Is there a maximum number of days Стопангин-Тева is intended to be used?

Regulatory documents advise that Стопангин-Тева is not intended for continuous long-term use. The maximum duration of continuous use is typically limited to 10 days. If symptoms persist or worsen beyond this timeframe, official warnings state that continued use beyond this period requires consultation with a healthcare professional.

---

Q: Can Стопангин-Тева cause an upset stomach or digestive issues?

The regulatory safety profile reports adverse reactions related to Gastrointestinal Disorders, most notably temporary taste disturbances (changes in taste sensation). The official safety data does not typically specify broader 'upset stomach' or systemic digestive issues outside of rare or systemic adverse reactions.

---

Q: Is it normal to feel a numbness or tingling sensation in the mouth after using the spray?

Official adverse reaction data includes reports of temporary disturbances of mucous membrane sensitivity. This indicates that localized sensations such as numbness or tingling at the site of application are documented effects associated with the use of the product.

---

Q: Can people who are pregnant use Стопангин-Тева?

The use of the product during pregnancy is generally not recommended by regulatory bodies because formal safety studies in pregnant women are currently lacking. Official documents indicate that the use of the product is generally restricted unless a healthcare provider determines that the potential benefit to the mother justifies the possible risk to the fetus.

---

Q: Is it safe to consume alcohol while using Стопангин-Тева?

The product itself contains ethanol (alcohol) in its formulation. Official warnings require consideration of this alcohol content, particularly if the solution is accidentally swallowed. Official safety information notes that individuals with a history of alcohol dependency must take caution and consider consulting a healthcare professional before using the preparation.

---

Q: Does the product lose effectiveness if it is exposed to heat or cold?

Official storage conditions mandate that the product must be kept at a temperature not exceeding 30 C. Regulatory bodies state that storage outside of the recommended temperature range may compromise the quality and stability of the product.

---

Q: Is it considered acceptable to use Стопангин-Тева while breastfeeding?

According to official product information, use while breastfeeding is generally not recommended. This caution is in place because it is not yet known whether hexetidine, the active ingredient, or its metabolites are excreted into breast milk. Decisions regarding use should involve evaluation by a healthcare provider to ensure that potential benefits justify any possible risks.

---

Q: What should be done if an accidental overdose of Стопангин-Тева occurs or if I swallow a small amount by accident?

The solution is strictly for local oromucosal use and must not be swallowed. If you accidentally ingest a small amount, or if an accidental overdose occurs, it is necessary to seek medical help immediately. This warning is provided due to the presence of ethanol (alcohol) in the product and the associated potential for symptoms related to alcohol ingestion.

Storage and Disposal Requirements for Стопангин-Тева

Official regulatory guidelines define specific conditions to maintain the stability and safety of this antiseptic product.

Storage Conditions

Requirement Category	Official Regulatory Statement
Maximum Temperature	Store at a temperature not exceeding 30 C
Protection from Light	Keep the product in the outer carton in order to protect from light
Child Safety	Must be kept out of the sight and reach of children

---

Disposal

Any unused or expired medicinal product or associated waste material must be disposed of in accordance with local requirements. This instruction mandates the use of designated pharmaceutical collection channels, as discarding the medicine in household waste or wastewater is generally prohibited by environmental regulations.